Antisoma, a cancer drug developer in London, England, and EcoBiotics, harnessing nature's chemistry for
contemporary drug discovery in Queensland, Australia, have entered into an agreement to study tropical rainforest plant compounds for possible
development of anti-cancer drugs. EcoBiotics will provide Antisoma with three compounds from the EcoBiotics
portfolio to evaluate during the next year. According to Antisoma's public announcement, EcoBiotics has a diverse portfolio of structurally defined and patent-protected molecules derived from tropical rainforest plants. A number of these molecules have already demonstrated anti-cancer activity in early preclinical assessments. All those evaluated by Antisoma will be small molecules that can be made by chemical synthesis.
